- Home
- AVTX vs CYCC Comparison
AVTX vs CYCC Comparison
Compare AVTX & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- CYCC
- Stock Information
- Founded
- AVTX 2011
- CYCC 1992
- Country
- AVTX United States
- CYCC Malaysia
- Employees
- AVTX N/A
- CYCC N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- CYCC Health Care
- Exchange
- AVTX Nasdaq
- CYCC Nasdaq
- Market Cap
- AVTX 57.4M
- CYCC 61.2M
- IPO Year
- AVTX 2015
- CYCC N/A
- Fundamental
- Price
- AVTX $4.41
- CYCC $1.66
- Analyst Decision
- AVTX Strong Buy
- CYCC
- Analyst Count
- AVTX 6
- CYCC 0
- Target Price
- AVTX $34.20
- CYCC N/A
- AVG Volume (30 Days)
- AVTX 62.6K
- CYCC 191.0K
- Earning Date
- AVTX 05-12-2025
- CYCC 05-15-2025
- Dividend Yield
- AVTX N/A
- CYCC 147.24%
- EPS Growth
- AVTX N/A
- CYCC N/A
- EPS
- AVTX N/A
- CYCC N/A
- Revenue
- AVTX $441,000.00
- CYCC $14,000.00
- Revenue This Year
- AVTX N/A
- CYCC $137.21
- Revenue Next Year
- AVTX N/A
- CYCC N/A
- P/E Ratio
- AVTX $0.59
- CYCC N/A
- Revenue Growth
- AVTX N/A
- CYCC N/A
- 52 Week Low
- AVTX $3.39
- CYCC $1.36
- 52 Week High
- AVTX $16.00
- CYCC $49.34
- Technical
- Relative Strength Index (RSI)
- AVTX 45.63
- CYCC 32.68
- Support Level
- AVTX $3.43
- CYCC $1.36
- Resistance Level
- AVTX $4.03
- CYCC $1.82
- Average True Range (ATR)
- AVTX 0.34
- CYCC 0.35
- MACD
- AVTX 0.09
- CYCC -0.04
- Stochastic Oscillator
- AVTX 70.47
- CYCC 9.73
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.